Prestige Biologics (KOSDAQ:A334970) secured a pharmaceutical manufacturing contract worth around 1.93 billion Korean won from an unnamed party, according to a Wednesday filing with the Korean Exchange.
The contract is expected to be fulfilled by July 31, 2026, the filing said.